ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Baltimore, MD, USA:

Descartes-25 in Relapsed/Refractory Multiple Myeloma

allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple...

Active, not recruiting
Relapse Multiple Myeloma
Multiple Myeloma
Drug: Descartes-25

Phase 1

Cartesian Therapeutics

Bethesda, Maryland, United States and 2 other locations

lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).FDA has approved selinexor plus dexamethaso ...

Enrolling
Plasma Cell Myeloma
Myeloma, Plasma Cell
Drug: Selinexor
Drug: Daratumumab

Phase 2

US Oncology Network
US Oncology Network

Columbia, Maryland, United States and 9 other locations

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients...

Enrolling
Multiple Myeloma
Drug: Teclistamab
Drug: Talquetamab

Phase 2

SCRI Development Innovations

Columbia, Maryland, United States and 11 other locations

CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15...

Enrolling
Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Drug: Descartes-15

Phase 1

Cartesian Therapeutics

Bethesda, Maryland, United States

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...

Enrolling
Multiple Myeloma
Drug: Ruxolitinib Oral Tablet [Jakafi]
Drug: Methylprednisolone

Phase 1

Oncotherapeutics

Bethesda, Maryland, United States and 12 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Columbia, Maryland, United States and 145 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Bendamustine
Drug: CC-95266

Phase 1

Juno Therapeutics

Baltimore, Maryland, United States and 9 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Baltimore, Maryland, United States and 31 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Baltimore, Maryland, United States and 59 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Baltimore, Maryland, United States and 211 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems